Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

HLS Therapeutics Inc

Healthcare CA HLS

4.425CAD
-0.005(0.11%)

Last update at 2026-06-04T16:04:00Z

Day Range

4.384.45
LowHigh

52 Week Range

4.175.76
LowHigh

Fundamentals

  • Previous Close 4.43
  • Market Cap145.42M
  • Volume900
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA17.19M
  • Revenue TTM55.50M
  • Revenue Per Share TTM1.76
  • Gross Profit TTM 39.71M
  • Diluted EPS TTM-0.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -13.10038M -15.58200M -27.80300M -23.72200M -11.80800M
Minority interest - - - - -
Net income -12.64759M -19.65500M -27.53100M -23.59800M -13.11700M
Selling general administrative 10.61M 10.20M 8.39M 17.73M 17.40M
Selling and marketing expenses 11.39M 16.73M 19.90M 17.85M 14.66M
Gross profit 24.01M 47.62M 55.45M 56.49M 56.04M
Reconciled depreciation 21.82M 22.72M 31.94M 34.40M 30.26M
Ebit -4.17788M -5.49900M -19.05500M -13.44000M -6.24000M
Ebitda 18.02M 17.22M 12.88M 20.96M 24.02M
Depreciation and amortization 22.20M 22.72M 31.94M 34.40M 30.26M
Non operating income net other - - - - -
Operating income -4.17788M -7.68600M -10.34900M -13.44000M -6.24000M
Other operating expenses 60.65M 64.31M 63.07M 74.96M 66.29M
Interest expense 7.22M 10.08M 8.75M 7.32M 6.96M
Tax provision -0.44500M 4.07M -0.27200M -0.12400M 1.31M
Interest income 0.11M 0.32M 0.35M 0.06M 0.04M
Net interest income -6.98600M -9.76400M -8.39800M -7.26000M -6.91200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.45279M 4.07M -0.27200M -0.12400M 1.31M
Total revenue 56.47M 56.62M 63.07M 61.47M 60.01M
Total operating expenses 28.19M 55.31M 55.45M 69.98M 62.32M
Cost of revenue 32.46M 9.00M 7.62M 4.98M 3.97M
Total other income expense net -8.92251M -7.89600M -17.45400M -10.28200M -5.56800M
Discontinued operations - - - - -
Net income from continuing ops -12.43000M -19.65500M -27.53100M -23.59800M -13.11700M
Net income applicable to common shares - -19.65500M -27.53100M -23.59800M -13.11700M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 137.28M 159.90M 209.06M 241.65M 275.90M
Intangible assets 105.43M 122.12M 162.34M 195.02M 229.18M
Earning assets - - - - -
Other current assets 1.37M - 1.92M 3.56M 4.52M
Total liab 75.72M 88.56M 111.36M 116.33M 115.17M
Total stockholder equity 61.56M 71.34M 97.70M 125.32M 160.74M
Deferred long term liab - - - - -
Other current liab 10.85M 0.03M 1.72M 6.01M 5.75M
Common stock 255.87M - 262.13M 265.21M 265.92M
Capital stock 256.34M 260.60M 262.13M 265.21M 265.92M
Retained earnings -203.78047M -194.18000M -175.45700M -148.44900M -119.85700M
Other liab - - - 1.38M 2.54M
Good will - - - - -
Other assets - - - 1.13M 1.40M
Cash 11.70M 17.46M 21.95M 20.72M 21.18M
Cash and equivalents - - - 20.72M 21.18M
Total current liabilities 26.07M 22.55M 26.69M 31.19M 27.67M
Current deferred revenue - - 5.71M - -
Net debt 38.03M 48.11M 65.67M 76.62M 76.39M
Short term debt 4.81M - 5.16M 13.58M 12.61M
Short long term debt 4.33M 4.83M 4.69M 13.06M 12.00M
Short long term debt total 49.73M - 87.62M 97.34M 97.57M
Other stockholder equity 16.13M - 13.87M 13.82M 11.72M
Property plant equipment - - - 1.13M 1.57M
Total current assets 29.04M 35.40M 44.09M 44.37M 43.75M
Long term investments - - - - -
Net tangible assets - - - -69.70000M -68.44500M
Short term investments - - - - -
Net receivables 7.85M 6.72M 10.69M 11.19M 11.51M
Long term debt 44.45M 60.74M 82.05M 83.28M 84.13M
Inventory 8.12M 9.06M 9.53M 8.90M 8.93M
Accounts payable 10.42M 8.71M 14.11M 11.59M 9.32M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -6.66784M - -2.83800M -5.26000M 2.96M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.33M 0.53M 0.62M 0.67M 0.71M
Deferred long term asset charges - - - - -
Non current assets total 108.24M 124.50M 164.97M 197.28M 232.15M
Capital lease obligations 1.04M 0.88M 0.88M 1.01M 1.43M
Long term debt total - - - 83.76M 84.96M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 11.73M -0.18900M -10.14800M -4.51000M
Change to liabilities - - - 3.24M -3.64600M
Total cashflows from investing activities -1.73281M 11.73M -0.18900M -10.14800M -4.51000M
Net borrowings -18.36900M -21.57300M -9.46300M -0.44100M -11.13700M
Total cash from financing activities -20.52105M -23.36400M -14.63900M -6.85600M -11.39800M
Change to operating activities - - - -0.70700M -1.73900M
Net income -12.64759M -19.65500M -27.53100M -23.59800M -13.11700M
Change in cash -6.57995M -4.49600M 1.23M -0.45600M 0.57M
Begin period cash flow 18.28M 21.95M 20.72M 21.18M 20.61M
End period cash flow 11.70M 17.46M 21.95M 20.72M 21.18M
Total cash from operating activities 16.02M 8.00M 15.79M 16.94M 16.43M
Issuance of capital stock - - - - -
Depreciation 22.20M 22.72M 31.94M 34.40M 30.26M
Other cashflows from investing activities - 13.25M -0.14800M -10.00000M -3.82000M
Dividends paid - 0.00000M -2.39800M 4.96M 5.12M
Change to inventory 1.30M -0.18900M -0.66100M -0.62200M 1.77M
Change to account receivables 0.00102M 2.37M 0.63M -0.07100M 1.04M
Sale purchase of stock -1.83049M -0.60000M -1.55200M -0.99800M -0.04700M
Other cashflows from financing activities -0.62475M -1.19100M -1.22600M 9.54M 4.91M
Change to netincome - - - 4.59M 2.30M
Capital expenditures 0.21M 0.01M 0.19M 10.15M 4.51M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.82M 1.14M 5.04M 1.55M -3.02100M
Stock based compensation 1.91M 1.62M -0.53800M 2.92M 2.35M
Other non cash items 2.97M -1.62900M 7.58M 1.53M -1.18700M
Free cash flow 15.81M 7.99M 15.60M 6.79M 11.92M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
HLS
HLS Therapeutics Inc		 -0.005 0.11% 4.42 - 31.95 2.62 1.71 2.60 8.99
CURA
Curaleaf Holdings Inc.		 0.34 7.19% 5.07 - 138.89 2.57 3.14 2.47 13.10
BHC
Bausch Health Companies Inc		 0.41 5.94% 7.31 13.98 1.35 0.28 18.74 2.12 6.84
CRON
Cronos Group Inc		 0.14 3.72% 3.90 - 32.15 9.80 0.95 1.47 1.90
TLRY
Tilray Inc		 0.06 0.84% 7.22 - 1000.00 1.28 0.53 1.08 -2.299

Reports Covered

Stock Research & News

View All

Profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLS Therapeutics Inc

10 Carlson Court, Etobicoke, ON, Canada, M9W 6L2

Key Executives

Name Title Year Born
Mr. Gregory David Gubitz B.A., L.L.B., LL.B Co-Founder & Chairman 1957
Mr. Gilbert Godin Co-Founder, CEO & Director 1959
Mr. Tim Hendrickson M.B.A. Chief Financial Officer 1972
Mr. Sanjiv Sharma Chief Commercial Officer 1956
Mr. Ryan C. Lennox B.A., J.D. Sr. VP of Legal, HR & Compliance and Corp. Sec. 1981
David Spence Corp. Controller 1968
Mr. Craig Stuart Millian M.B.A. CEO & Director 1968
Mr. John Hanna CPA, CGA, M.B.A. CFO & Non-Independent Director 1965
Dr. Jason A. Gross Pharm.D. Vice President of Scientific Affairs 1965
Mr. Ryan C. Lennox B.A., J.D. Senior VP of Legal, HR & Compliance and Corporate Secretary 1981

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.